卡马替尼

Description

Capmatinib · CAS 1029712-80-8 · C23H17FN6O. UNII TY34L4F9OZ.

Identification

CAS Registry Number	1029712-80-8
PubChem CID	25145656
Molecular formula	C23H17FN6O
IUPAC name	2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
UNII (FDA)	TY34L4F9OZ

Computed Descriptors

Molecular Weight	412.4
XLogP3	2.9
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	4
Exact Mass	412.14478735
Monoisotopic Mass	412.14478735
Topological Polar Surface Area	85.1
Heavy Atom Count	31
Formal Charge	0

GHS Hazard Classification

Reported hazard statements	H301 (100%), H360 (25%), H373 (100%), H411 (100%)

Documented Uses

• In the US, capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. Capmatinib is approved to treat adults with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations in Canada.
• Capmatinib is an orally available, small molecule inhibitor of the mesenchymal-epithelial transition (MET) factor tyrosine kinase receptor that is used in selected patients with non-small cell lung cancer (NSCLC). Serum aminotransferase elevations are common during therapy with capmatinib, which rarely can lead to clinically apparent liver injury that can be severe and even fatal.
• Breast Feeding; Lactation; Milk, Human; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors
• Take with or without food. Co-administration with high-fat meals slightly alters AUC, but not to a clinically significant extent.
• Established Pharmacologic Class [EPC] - Kinase Inhibitor
• Mechanisms of Action [MoA] - Mesenchymal Epithelial Transition Inhibitors

Synonyms

capmatinib; 1029712-80-8; INCB28060; INC-280; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INCB-28060; NVP-INC280-NX; INCB 28060; NVP-INC280; TY34L4F9OZ; 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; INCB-28060 FREE BASE; DTXSID90145595; 2-fluoro-N-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide; capmatinibum

Frequently Asked Questions

What are the CAS number and molecular formula of Capmatinib?

CAS 1029712-80-8; molecular formula C23H17FN6O; molecular weight — g/mol.

What other names is Capmatinib known by?

capmatinib, 1029712-80-8, INCB28060, INC-280, 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide, INCB-28060.

Is Capmatinib classified as hazardous?

Hazard statements reported: H301, H360, H373, H411.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.